When trying to sell a prescription medicine, not all countries are created equal. offers a case in point. Shares in the biotech company fell by 60% Friday after the company announced that the Food and Drug Administration had denied regulatory approval for Vitaros, its topical cream to treat erectile dysfunction. That might have surprised investors […]

Source: Wall Street Journal February 16, 2018 16:24 UTC